Advanced search

Vol 27 (2024): Continuous Publishing
Guidelines / Expert consensus
Published online: 2024-11-25

open access

View PDF Download PDF file
Page views 117
Article views/downloads 64
Get Citation

Connect on Social Media

Connect on Social Media

Current state and prospects for the development of nuclear medicine in Poland

Anna Teresińska1, Renata Mikołajczak2, Barbara Jarząb3, Leszek Królicki4, Anna Płachcińska5, Janusz Braziewicz67, Magdalena Kostkiewicz89, Mirosław Dziuk10, Bożena Birkenfeld11, Bogdan Małkowski12
DOI: 10.5603/nmr.102810
Nucl. Med. Rev 2024;27:42-52.

Abstract

The aim of the report is to present the current state of equipment, radiopharmacy, dosimetry, and selected clinical applications, together with proposed new solutions and expected directions of development of classic nuclear medicine and positron emission tomography (PET). The statement presents the individual points of view of the members of the Commission for Nuclear Medicine of the Committee of Medical Physics, Radiobiology and Diagnostic Imaging of the Polish Academy of Sciences in the 2020–2023 term.

Keywords: single photon emission tomography/computed tomographypositron emission tomography/ /computed tomographyscintigraphyradioisotope therapyradiopharmacytherapeutic dosimetry

Article available in PDF format

View PDF Download PDF file

References

  1. Kunikowska J, Królicki L, Czepczyński R. Nuclear imaging and therapy in oncology in Poland in 2021–2022. Eur J Nucl Med Mol Imaging. 2023; 50(8): 2236–2239.
    CrossRefPubMed
  2. Akamatsu Go, Tsutsui Y, Daisaki H, et al. A review of harmonization strategies for quantitative PET. Ann Nucl Med. 2023; 37(2): 71–88.
    CrossRefPubMed
  3. Aide N, Lasnon C, Veit-Haibach P, et al. EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging. 2017; 44(Suppl 1): 17–31.
    CrossRefPubMed
  4. Dziennik Urzędowy Ministra Zdrowia. https://www.gov.pl/ (26.09.2024).
  5. Rejestry e-zdrowie. https://rejestry.ezdrowie.gov.pl/rpl/search/public (26.09.2024).
  6. Gillings N, Hjelstuen O, Ballinger J, et al. Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. EJNMMI Radiopharm Chem. 2021; 6(1): 8.
    CrossRefPubMed
  7. Kunikowska J, Zemczak A, Kołodziej M, et al. Tandem peptide receptor radionuclide therapy using Y/Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience. Eur J Nucl Med Mol Imaging. 2020; 47(4): 922–933.
    CrossRefPubMed
  8. Hubalewska-Dydejczyk A, Fröss-Baron K, Mikołajczak R, et al. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging. 2006; 33(10): 1123–1133.
    CrossRefPubMed
  9. Sowa-Staszczak A, Pach D, Mikołajczak R, et al. Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. Eur J Nucl Med Mol Imaging. 2013; 40(4): 524–531.
    CrossRefPubMed
  10. Lezaic L, Erba PA, Decristoforo C, et al. [In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial. Eur J Nucl Med Mol Imaging. 2023; 50(3): 892–907.
    CrossRefPubMed
  11. Opalinska M, Lezaic L, Decristoforo C, et al. Comparison of 99mTc radiolabeled somatostatin antagonist with [ Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor. Eur J Nucl Med Mol Imaging. 2023; 50(13): 4110–4111.
    CrossRefPubMed
  12. Petranović Ovčariček P, Giovanella L, Carrió Gasset I, et al. The EANM practice guidelines for parathyroid imaging. Eur J Nucl Med Mol Imaging. 2021; 48(9): 2801–2822.
    CrossRefPubMed
  13. Ricciato MP, Di Donna V, Perotti G, et al. The role of adrenal scintigraphy in the diagnosis of subclinical Cushing's syndrome and the prediction of post-surgical hypoadrenalism. World J Surg. 2014; 38(6): 1328–1335.
    CrossRefPubMed
  14. Powlson AS, Gurnell M, Brown MJ. Nuclear imaging in the diagnosis of primary aldosteronism. Curr Opin Endocrinol Diabetes Obes. 2015; 22(3): 150–156.
    CrossRefPubMed
  15. Koffas A, Giakoustidis A, Papaefthymiou A, et al. Diagnostic work-up and advancement in the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. Front Surg. 2023; 10: 1064145.
    CrossRefPubMed
  16. Mikołajczak R, Maecke HR. Radiopharmaceuticals for somatostatin receptor imaging. Nucl Med Rev Cent East Eur. 2016; 19(2): 126–132.
    CrossRefPubMed
  17. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med. 2000; 41: 1704–1713.
    PubMed
  18. Kolasińska-Ćwikła A, Łowczak A, Maciejkiewicz KM, et al. Peptide receptor radionuclide therapy for advanced gastroenteropancreatic neuroendocrine tumors — from oncology perspective. Nucl Med Rev Cent East Eur. 2018; 21(2): 115–124.
    CrossRefPubMed
  19. Rudisile S, Gosewisch A, Wenter V, et al. Salvage PRRT with Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival. BMC Cancer. 2019; 19(1): 788.
    CrossRefPubMed
  20. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40(2): 87–165.
    CrossRefPubMed
  21. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020; 41(3): 407–477.
    CrossRefPubMed
  22. Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024; 45(36): 3415–3537.
    CrossRefPubMed
  23. Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2021; 42(6): 563–645.
    CrossRefPubMed
  24. Halvorsen S, Mehilli J, Cassese S, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022; 43(39): 3826–3924.
    CrossRefPubMed
  25. Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022; 43(40): 3997–4126.
    CrossRefPubMed
  26. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022; 43(41): 4229–4361.
    CrossRefPubMed
  27. Teresińska A, Królicki L. Registry of nuclear medicine procedures in cardiology in Poland in 2019–2021. Nucl Med Rev Cent East Eur. 2023; 26: 158–164.
    CrossRefPubMed
  28. Werner RA, Thackeray JT, Diekmann J, et al. The changing face of nuclear cardiology: guiding cardiovascular care toward molecular medicine. J Nucl Med. 2020; 61(7): 951–961.
    CrossRefPubMed
  29. Bourque JM, Beller GA. Nuclear cardiology: the past, present, and future. Circ Cardiovasc Imaging. 2024; 17(5): e016875.
    CrossRefPubMed
  30. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023; 44(37): 3503–3626.
    CrossRefPubMed
  31. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016; 133(24): 2404–2412.
    CrossRefPubMed
  32. Dorbala S, Kijewski MF. Molecular imaging of systemic and cardiac amyloidosis: recent advances and focus on the future. J Nucl Med. 2023; 64(Suppl 2): 20S–28S.
    CrossRefPubMed
  33. Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC Guidelines for the management of endocarditis. Eur Heart J. 2023; 44(39): 3948–4042.
    CrossRefPubMed
  34. Bourque JM, Birgersdotter-Green U, Bravo PE, et al. F-FDG PET/CT and radiolabeled leukocyte SPECT/CT imaging for the evaluation of cardiovascular infection in the multimodality context: ASNC imaging indications (ASNC I) series expert consensus recommendations from ASNC, AATS, ACC, AHA, ASE, EANM, HRS, IDSA, SCCT, SNMMI, and STS. JACC Cardiovasc Imaging. 2024; 17(6): 669–701.
    CrossRefPubMed
  35. Besson FL, Parienti JJ, Bienvenu B, et al. Diagnostic performance of ¹⁸F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011; 38(9): 1764–1772.
    CrossRefPubMed
  36. Barra L, Kanji T, Malette J, et al. CanVasc. Imaging modalities for the diagnosis and disease activity assessment of Takayasu's arteritis: a systematic review and meta-analysis. Autoimmun Rev. 2018; 17(2): 175–187.
    CrossRefPubMed
  37. Dejaco C, Ramiro S, Bond M, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis. 2024; 83(6): 741–751.
    CrossRefPubMed
  38. Lauri C, Signore A, Glaudemans AW, et al. Evidence-based guideline of the European Association of Nuclear Medicine (EANM) on imaging infection in vascular grafts. Eur J Nucl Med Mol Imaging. 2022; 49(10): 3430–3451.
    CrossRefPubMed
  39. Reinders Folmer EI, Von Meijenfeldt GCI, Van der Laan MJ, et al. Diagnostic imaging in vascular graft infection: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg. 2018; 56(5): 719–729.
    CrossRefPubMed
  40. Puges M, Bérard X, Ruiz JB, et al. Retrospective study comparing WBC scan and F-FDG PET/CT in patients with suspected prosthetic vascular graft infection. Eur J Vasc Endovasc Surg. 2019; 57(6): 876–884.
    CrossRefPubMed
  41. Joshi NV, Vesey AT, Williams MC, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet. 2014; 383(9918): 705–713.
    CrossRefPubMed
  42. Kwiecinski J, Dey D, Cadet S, et al. Predictors of 18F-sodium fluoride uptake in patients with stable coronary artery disease and adverse plaque features on computed tomography angiography. Eur Heart J Cardiovasc Imaging. 2020; 21(1): 58–66.
    CrossRefPubMed
  43. Kwiecinski J, Tzolos E, Adamson PD, et al. Coronary f-sodium fluoride uptake predicts outcomes in patients with coronary artery disease. J Am Coll Cardiol. 2020; 75(24): 3061–3074.
    CrossRefPubMed
  44. Kwiecinski J, Tzolos E, Meah MN, et al. Machine learning with f-sodium fluoride PET and quantitative plaque analysis on CT angiography for the future risk of myocardial infarction. J Nucl Med. 2022; 63(1): 158–165.
    CrossRefPubMed
  45. Fletcher AJ, Tew YY, Tzolos E, et al. Thoracic aortic f-sodium fluoride activity and ischemic stroke in patients with established cardiovascular disease. JACC Cardiovasc Imaging. 2022; 15(7): 1274–1288.
    CrossRefPubMed
  46. Hyafil F, Gimelli A, Slart RH, et al. EANM procedural guidelines for myocardial perfusion scintigraphy using cardiac-centered gamma cameras. Eur J Hybrid Imaging. 2019; 3(1): 11.
    CrossRefPubMed
  47. Wells RG, Small GR, Ruddy TD. Myocardial blood flow quantification with SPECT. J Med Imaging Radiat Sci. 2024; 55(2S): S51–S58.
    CrossRefPubMed
  48. Fahey FH, Grant FD, Thrall JH. Saul Hertz, MD, and the birth of radionuclide therapy. EJNMMI Phys. 2017; 4(1): 15.
    CrossRefPubMed
  49. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016; 26(1): 1–133.
    CrossRefPubMed
  50. Jarząb B, Dedecjus M, Lewiński A, et al. Diagnosis and treatment of thyroid cancer in adult patients — recommendations of Polish Scientific Societies and the National Oncological Strategy. 2022 Update. Endokrynol Pol. 2022; 73(2): 173–300.
    CrossRef
  51. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26(13): 2124–2130.
    CrossRefPubMed
  52. Strosberg JR, Srirajaskanthan R, El-Haddad G, et al. Phase 3 trial of lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017; 376(2): 125–135.
    CrossRefPubMed
  53. Morris MJ, Sartor O, de Bono JS, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021; 385(12): 1091–1103.
    CrossRefPubMed
  54. Hoskin P, Sartor O, O'Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014; 15(12): 1397–1406.
    CrossRefPubMed
  55. Andersson M, Johansson L, Minarik D, et al. Effective dose to adult patients from 338 radiopharmaceuticals estimated using ICRP biokinetic data, ICRP/ICRU computational reference phantoms and ICRP 2007 tissue weighting factors. EJNMMI Phys. 2014; 1(1): 9.
    CrossRefPubMed
  56. Cremonesi M, Ferrari M, Bodei L, et al. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006; 47(9): 1467–1475.
    PubMed
  57. Taprogge J, Wadsley J, Miles E, et al. Recommendations for multicentre clinical trials involving dosimetry for molecular radiotherapy. Clin Oncol (R Coll Radiol). 2021; 33(2): 131–136.
    CrossRefPubMed
  58. Sundlöv A, Sjögreen-Gleisner K, Svensson J, et al. Individualised Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017; 44(9): 1480–1489.
    CrossRefPubMed
  59. Wadsley J, Flux G. Molecular radiotherapy comes of age. Clin Oncol (R Coll Radiol). 2021; 33(2): 65–67.
    CrossRefPubMed
  60. Haug AR. PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme? EJNMMI Res. 2020; 10(1): 35.
    CrossRefPubMed
  61. Konijnenberg M, Herrmann K, Kobe C, et al. EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy. Eur J Nucl Med Mol Imaging. 2021; 48(1): 67–72.
    CrossRefPubMed
  62. ICRU Report 96. Dosimetry-Guided Radiopharmaceutical Therapy, 2021.

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note